candesartan cilexetil has been researched along with Endomyocardial Fibrosis in 3 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Endomyocardial Fibrosis: A condition characterized by the thickening of the ventricular ENDOCARDIUM and subendocardium (MYOCARDIUM), seen mostly in children and young adults in the TROPICAL CLIMATE. The fibrous tissue extends from the apex toward and often involves the HEART VALVES causing restrictive blood flow into the respective ventricles (CARDIOMYOPATHY, RESTRICTIVE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recently, it has been suggested that angiotensin II (AII) might be associated with cardiac hypertrophy and fibrosis." | 3.69 | Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats. ( Dohi, K; Iwano, M; Kagoshima, T; Konishi, N; Masuda, J; Nakamura, Y; Sakaguchi, Y; Sutani, T; Tsuchihashi, M; Tsuruta, S, 1994) |
| "When candesartan cilexetil was administered to Bio TO2 hamsters, cardiac chymase-like activity increased significantly, whereas cardiac fibrosis decreased significantly." | 1.33 | Effect of Angiotensin II Type 1 receptor blocker on cardiac angiotensin-converting enzyme and chymase-like activities, and cardiac fibrosis in cardiomyopathic hamsters. ( Orito, K; Shimamura, S; Shimizu, M; Tanaka, R; Uchida, M; Yamane, Y, 2006) |
| "DOCA-salt hypertension was induced in 8-wk-old male Wistar rats by uninephrectomy and administration of DOCA (25 mg every fourth day, subcutaneously) and 1% NaCl in the drinking water for 4 wk." | 1.30 | Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. ( Brown, L; Duce, B; Miric, G; Sernia, C, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shimizu, M | 1 |
| Tanaka, R | 1 |
| Uchida, M | 1 |
| Orito, K | 1 |
| Shimamura, S | 1 |
| Yamane, Y | 1 |
| Kagoshima, T | 1 |
| Masuda, J | 1 |
| Sutani, T | 1 |
| Sakaguchi, Y | 1 |
| Tsuchihashi, M | 1 |
| Tsuruta, S | 1 |
| Iwano, M | 1 |
| Dohi, K | 1 |
| Nakamura, Y | 1 |
| Konishi, N | 1 |
| Brown, L | 1 |
| Duce, B | 1 |
| Miric, G | 1 |
| Sernia, C | 1 |
3 other studies available for candesartan cilexetil and Endomyocardial Fibrosis
| Article | Year |
|---|---|
Effect of Angiotensin II Type 1 receptor blocker on cardiac angiotensin-converting enzyme and chymase-like activities, and cardiac fibrosis in cardiomyopathic hamsters.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Body Weight; C | 2006 |
Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1994 |
Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 1999 |